Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Moreau P, et al. Among authors: attal m. Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Lancet. 2019. PMID: 31171419 Clinical Trial.
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Among authors: attal m. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.
High-dose therapy in multiple myeloma.
Harousseau JL, Attal M. Harousseau JL, et al. Among authors: attal m. Hematol J. 2003;4(3):163-70. doi: 10.1038/sj.thj.6200259. Hematol J. 2003. PMID: 12764348 Review. No abstract available.
Single versus double autologous stem-cell transplantation for multiple myeloma.
Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Attal M, et al. N Engl J Med. 2003 Dec 25;349(26):2495-502. doi: 10.1056/NEJMoa032290. N Engl J Med. 2003. PMID: 14695409 Free article. Clinical Trial.
Stem-cell transplantation in multiple myeloma.
Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Harousseau JL, et al. Among authors: attal m. Best Pract Res Clin Haematol. 2005;18(4):603-18. doi: 10.1016/j.beha.2005.01.005. Best Pract Res Clin Haematol. 2005. PMID: 16026740 Review.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome group. Moreau P, et al. Among authors: attal m. Blood. 2006 Jan 1;107(1):397-403. doi: 10.1182/blood-2005-06-2573. Epub 2005 Sep 6. Blood. 2006. PMID: 16144800 Free article. Clinical Trial.
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, Harousseau JL, Eschard JP, Ferrant A, Blanc M, Maloisel F, Orfeuvre H, Rossi JF, Azaïs I, Monconduit M, Collet P, Anglaret B, Yakoub-Agha I, Wetterwald M, Eghbali H, Vekemans MC, Maisonneuve H, Troncy J, Grosbois B, Doyen C, Thyss A, Jaubert J, Casassus P, Thielemans B, Bataille R; Intergroupe Francophone du Myélome (IFM) group. Facon T, et al. Among authors: attal m. Blood. 2006 Feb 15;107(4):1292-8. doi: 10.1182/blood-2005-04-1588. Epub 2005 Sep 20. Blood. 2006. PMID: 16174762 Free article. Clinical Trial.
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D. Jourdan E, et al. Among authors: attal m. J Clin Oncol. 2005 Oct 20;23(30):7676-84. doi: 10.1200/JCO.2005.02.5940. Epub 2005 Sep 26. J Clin Oncol. 2005. PMID: 16186596 Clinical Trial.
339 results